|
시장보고서
상품코드
2075134
인슐린·리스프로 시장 : 인슐린·리스프로 제품 유형별, 적응증별, 연령층별, 약제 클래스별, 유통 채널별, 지역별Insulin Lispro Market, By Product Type of Insulin Lispro, By Indication, By Age Group, By Drug Class, By Distribution Channel, By Geography |
||||||
인슐린·리스프로 시장은 2026년에 87억 8,000만 달러 규모에 달할 것으로 추정되고 있으며, 2033년까지 135억 5,000만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 6.4%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 87억 8,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 6.40% | 2033년 시장 규모 예측 : | 135억 5,000만 달러 |
인슐린 리스프로는 인슐린 치료가 필요한 제1형 당뇨병(신체가 인슐린을 생성하지 못해 혈당 수치를 조절할 수 없는 상태)의 치료에 사용됩니다. 외부 인슐린 펌프와 병용하는 경우를 제외하고는 항상 다른 유형의 인슐린과 병용하여 사용됩니다. 또한 인슐린 리스프로 주사제는 경구용 약물만으로는 충분한 효과를 얻을 수 없는 제2형 당뇨병 성인 환자의 혈당 조절을 개선하기 위해 사용되기도 합니다. 인슐린 리스프로는 아나로그 인슐린의 일종으로, 인간 인슐린과는 B-28 위치에 있는 프롤린과 B-29 위치에 있는 리신이라는 두 아미노산의 서열이 다르다는 점이 특징입니다. 이러한 변화로 인해 인슐린이 이량체나 육량체를 형성하는 것을 막습니다. 이량체나 육량체는 단량체 인슐린에 비해 활성이 낮아집니다. 인슐린 리스프로는 피하 투여 후 신속하게 흡수되어 2-4시간 이내에 혈중 농도가 최고치에 도달하며, 18-30시간 동안 효과가 지속됩니다.
시장 역학 :
전 세계 리스프로 인슐린 시장은 주로 당뇨병 환자 수의 증가와 인슐린 투여 기기 분야의 기술적 진보에 힘입어 최근 수년간 눈에 띄게 성장하고 있습니다. 이러한 성장은 의료 서비스 개선을 위한 정부의 노력 강화, 인슐린에 대한 환자 수요 증가, 나아가 선진국의 유리한 의료비 환급 정책 등의 요인에 힘입어 더욱 가속화될 것으로 예상됩니다. 자주 앉아 있는 생활 습관이나 불건강한 식생활의 확산과 같은 라이프스타일의 변화로 인해 전 세계에서 당뇨병 발병자 수가 증가하고 있습니다. 국제당뇨병연맹(IDF)에 따르면 2021년에는 약 5억 3,700만 명의 성인이 당뇨병을 앓고 있었으며, 이 수치는 2030년까지 6억 4,300만 명, 2045년까지 7억 8,400만 명으로 증가할 것으로 예상됩니다. 비만율의 상승과 앉아 있는 시간이 많은 생활 습관의 증가가 당뇨병 환자 수의 증가에 크게 기여하고 있습니다. 그러나 인슐린 아날로그의 높은 비용과 바이오시밀러 제제의 보급은 여전히 시장 성장에 있으며, 과제로 남아 있습니다. 한편, 개발도상국에서 정부의 적극적인 노력과 의료 서비스 접근성 개선은 이 시장에서 사업을 운영하는 기업에게 유망한 기회를 제공하고 있습니다. 또한 아날로그 인슐린 투여 기기 및 제제의 개발도 향후 시장 동향을 좌우하는 요인이 될 것입니다.
본 조사의 주요 특징 :
- 본 조사에서는 다양한 부문의 잠재적 매출 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하는 경쟁 전략에 관한 중요 인사이트를 제공합니다.
- 본 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 인슐린 리스프로 시장의 주요 기업 개요을 소개하고 있습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 유형 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 이 보고서는 전 세계 인슐린 리스프로 시장에 관한 것으로, 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 인슐린 리스프로 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 원활하게 의사결정을 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 인슐린·리스프로 시장 : 인슐린·리스프로 제품 유형별, 2021-2033년
제5장 인슐린·리스프로 시장 : 적응증별, 2021-2033년
제6장 인슐린·리스프로 시장 : 연령층별, 2021-2033년
제7장 인슐린·리스프로 시장 : 약제 클래스별, 2021-2033년
제8장 인슐린·리스프로 시장 : 유통 채널별, 2021-2033년
제9장 인슐린·리스프로 시장 : 지역별, 2021-2033년
제10장 경쟁 구도
제11장 섹션
KSA 26.07.07Insulin Lispro Market is estimated to be valued at USD 8.78 Bn in 2026 and is expected to reach USD 13.55 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.4% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 8.78 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.40% | 2033 Value Projection: | USD 13.55 Bn |
Insulin lispro is used to treat type 1 diabetes (a condition in which the body does not produce insulin and cannot control the amount of sugar in the blood) in people who need insulin therapy. It is always used with another type of insulin, unless it is being used with an external insulin pump. Insulin lispro injection products are also used to improve glycemic control in adults with type 2 diabetes who do not respond well to oral medications alone. Insulin lispro is an analog insulin that differs from human insulin with a change in the sequence of two amino acids, proline at B-28 and lysine at B-29. This change prevents insulin from forming dimers and hexamers, which have lower activity than monomeric insulin. Insulin lispro is rapidly absorbed following subcutaneous administration, reaching peak levels within 2-4 hours and remaining effective for 18-30 hours.
Market Dynamics:
The global insulin lispro market has grown significantly in recent years, primarily due to an increase in the number of people living with diabetes and technological advancements in the field of insulin delivery devices. This growth is further expected to be supported by factors such as increasing government initiatives to improve healthcare and rising patient demand for insulin, as well as favorable medical reimbursement policies in developed countries. Changing lifestyles, such as an increased adoption of sedentary habits and unhealthy diets, have resulted in an increased number of people developing diabetes globally. As per the International Diabetes Federation, approximately 537 Mn adults were living with diabetes in 2021, and this number is expected to rise to 643 Mn by 2030 and 784 Mn by 2045. The increasing obesity rates and sedentary lifestyles have significantly contributed to this rise in diabetes cases. However, the high costs of insulin analogs and the availability of biosimilar alternatives remain a challenge for market growth. On the positive side, favorable government initiatives and improved access to healthcare services in developing nations present lucrative opportunities for players operating in this market. Developments in analog insulin delivery devices and formulations will also likely shape the future dynamics.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global insulin lispro market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Eli Lilly and Company, Sanofi, Novo Nordisk A/S, Merck & Co., Inc., Pfizer Inc., Hoffmann-La Roche Ltd., AstraZeneca PLC, Johnson & Johnson Services, Inc., Biocon Limited, Mylan N.V., Boehringer Ingelheim, International GmbH, Wockhardt Ltd., Lupin Pharmaceuticals, Inc., Bioton S.A., Gan & Lee Pharmaceuticals and Ypsomed AG
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global insulin lispro market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global insulin lispro market
Insulin Lispro Market Detailed Segmentation:
- By Product Type (Revenue, USD Bn, 2021 - 2033)
- Insulin Lispro pre-filled pen
- Insulin lispro solution vials
- Insulin lispro solution cartridge
- By Indication (Revenue, USD Bn, 2021 - 2033)
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Others
- By Age Group (Revenue, USD Bn, 2021 - 2033)
- Pediatric Patients
- Adult Patients
- Geriatric Patients
- By Drug Class (Revenue, USD Bn, 2021 - 2033)
- Humalog (Eli Lilly and Company)
- Admelog (Sanofi)
- Other brands
- By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles
- Eli Lilly and Company
- Sanofi
- Novo Nordisk A/S
- Merck & Co., Inc.
- Pfizer Inc.
- Hoffmann-La Roche Ltd.
- AstraZeneca PLC
- Johnson & Johnson Services, Inc.
- Biocon Limited
- Mylan N.V.
- Boehringer Ingelheim International GmbH
- Wockhardt Ltd.
- Lupin Pharmaceuticals, Inc.
- Bioton S.A.
- Gan & Lee Pharmaceuticals
- Ypsomed AG
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Insulin Lispro, By Product Type of Insulin Lispro
- Market Insulin Lispro, By Indication
- Market Insulin Lispro, By Age Group
- Market Insulin Lispro, By Drug Class
- Market Insulin Lispro, By Distribution Channel
- Market Insulin Lispro, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Growing prevalence of diabetes
- Restrains
- Opportunities
- Growing launch of new product
- Drivers
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER€(TM)s Analysis
- Merger and Acquisition Scenario
4. Insulin Lispro Market , By Product Type of Insulin Lispro, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 €" 2033
- Segment Trends
- Insulin Lispro pre-filled pen
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Insulin lispro solution vials
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Insulin lispro solution cartridge
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
5. Insulin Lispro Market , By Indication, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 €" 2033
- Segment Trends
- Type 1 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Type 2 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Gestational Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
6. Insulin Lispro Market , By Age Group, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 €" 2033
- Segment Trends
- Paediatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Adult Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Geriatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
7. Insulin Lispro Market , By Drug Class, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 €" 2033
- Segment Trends
- Humalog (Eli Lilly and Company)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Admelog (Sanofi)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Other Brands
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
8. Insulin Lispro Market , By Distribution Channel, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 €" 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
9. Insulin Lispro Market , By Region, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, By Country, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Country 2026 €"2033
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type of Insulin Lispro, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country 2021 - 2033,(US$ Bn)
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type of Insulin Lispro, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country 2021 - 2033,(US$ Bn)
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type of Insulin Lispro, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country 2021 - 2033,(US$ Bn)
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type of Insulin Lispro, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country 2021 - 2033,(US$ Bn)
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type of Insulin Lispro, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country 2021 - 2033,(US$ Bn)
10. Competitive Landscape
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Johnson & Johnson Services, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Biocon Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Wockhardt Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Lupin Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bioton S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Gan & Lee Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Ypsomed AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
11. Section
- Research Methodology
- About us
